• Explore /
  • Poster
  • / Investigating denosumab as add-on neoadjuvant treatment for hormone receptor-negative, RANK-positive or RANK-negative primary breast cancer and two different nab-Paclitaxel schedules - 2x2 factorial design (GeparX).

Investigating denosumab as add-on neoadjuvant treatment for hormone receptor-negative, RANK-positive or RANK-negative primary breast cancer and two different nab-Paclitaxel schedules - 2x2 factorial design (GeparX).

Abstract Poster

Authors

null

Sherko Kümmel

Department of Senology / Breast Care Center, Kliniken Essen Mitte, Essen, Germany

Sherko Kümmel , Gunter Von Minckwitz , Valentina Nekljudova , Serban Dan Costa , Carsten Denkert , Claus Hanusch , Jens Bodo Huober , Christian Jackisch , Stefan Paepke , Jens Uwe Blohmer , Michael Untch , Andreas Schneeweiss , Sibylle Loibl

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—HER2/ER

Track

Breast Cancer

Sub Track

HER2+

Clinical Trial Registration Number

EudraCT No.: 2015-001755-72

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS635)

DOI

10.1200/JCO.2016.34.15_suppl.TPS635

Abstract #

TPS635

Poster Bd #

112a

Abstract Disclosures

Similar Posters

First Author: Sherko Kummel

First Author: Naoko Matsuda

First Author: Renske Kornalijnslijper-Altena

First Author: Esther Pohl-Rescigno